Drug-specific T-cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat.

Paul J ThomsonLaila KafuXiaoli MengJan SnoeysAn De BondtDries De MaeyerHans WilsLaurent LeclercqPetra VinkenDean John Naisbitt

Published in: Allergy (2020)

The detection of atabecestat metabolite-responsive T-cell clones activated via a pharmacological interactions pathway in patients with liver injury is indicative of an immune-based mechanism for the observed hepatic enzyme elevations.

Keyphrases

liver injury
drug induced
adverse drug
loop mediated isothermal amplification
emergency department
drug delivery
label free